Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW597901X · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| GW597901X | DRUG | - |
Inclusion criteria: * Subjects with mild to moderate stable asthma but no other lung problems. * Male subjects or female subjects who are not able to get pregnant (e.g. post-menopausal or surgically sterile). * Non-Smokers. * Subjects who show a measurable improvement in the function of their lungs...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
GW597901X is an investigational small molecule being developed for the treatment of asthma. It is administered via inhalation and is intended to affect lung function in asthmatic patients. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
GW597901X is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the safety and effects of this investigational drug in patients with asthma.
GW597901X is in Phase 1 clinical development. A Phase 1 trial has been completed to assess the safety and lung function effects of repeat inhaled doses in asthmatic subjects. The drug remains investigational and has not received approval for commercial use.
GW597901X has one completed clinical trial registered under NCT00354042, titled 'Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Function In Asthmatic Subjects.' This Phase 1 study enrolled 24 participants with asthma and was completed, with no active trials currently ongoing.
GW597901X is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for asthma. The completed Phase 1 trial focused on safety and lung function, but the drug has not yet progressed to later-stage trials or received regulatory approval.